InFocus Capital Partners

Visibly, Inc. is a healthcare technology company based in Chicago, Illinois, that specializes in online eye examination services for patients across the United States. Originally known as Opternative, Inc., the company rebranded in November 2018. Visibly offers a refractive eye exam to measure prescriptions for glasses and contact lenses, providing a digital solution for vision care. Its products cater to a variety of sectors, including e-commerce employers, eye care providers, insurance companies, online healthcare platforms, and optical retail. By offering a virtual vision testing technology, Visibly ensures that patients can conveniently renew their prescriptions and address their eye health needs from anywhere at any time, enhancing accessibility to essential eye care services.

Re-Vana Therapeutics Ltd is an ocular pharmaceuticals and drug delivery company based in Belfast, United Kingdom, established in 2016. The company specializes in the development and commercialization of innovative biodegradable drug delivery platforms aimed at treating chronic eye diseases, including age-related macular degeneration, diabetic retinopathy, glaucoma, and ocular infections. Re-Vana’s platforms, OcuLief and EyeLief, are designed for long-acting, tailored delivery of therapeutics, allowing for sustained release of active ingredients over periods ranging from one week to one year. OcuLief is specifically developed for age-related macular degeneration and diabetic retinopathy, while EyeLief targets glaucoma and retinal diseases. The company employs FDA-approved polymers in its technology, focusing on enhancing patient compliance by minimizing treatment frequency, reducing pain, and lowering side effects. By providing versatile delivery options, Re-Vana aims to facilitate cost savings for healthcare providers and pharmaceutical companies while improving patient outcomes.

Stuart Therapeutics is a biotechnology company focused on developing innovative therapies for ophthalmic conditions. The company's primary offering, PolyCol, is a synthesized peptide therapeutic platform designed to repair disease-damaged helical collagen in the eye. This platform facilitates accelerated healing of epithelial cells, restoration of nerve function, and reduction of inflammation, making it a promising treatment for various ophthalmic diseases, including dry eye disease, dry age-related macular degeneration, and glaucoma. PolyCol is based on patented research from a major U.S. university, supplemented by additional intellectual property acquired by the company. Beyond ophthalmic applications, Stuart Therapeutics is also exploring PolyCol's potential in treating gastrointestinal, inflammatory, and oncology conditions.

ONL Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies to protect and improve vision in patients with retinal diseases. Established in 2006, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway, offering potential protection for photoreceptors. Its drug programs are designed to address serious, vision-threatening conditions, including retinal detachment, ultimately aiming to enhance surgical outcomes and patient quality of life through the use of small-molecule peptides.

Re-Vana Therapeutics Ltd is an ocular pharmaceuticals and drug delivery company based in Belfast, United Kingdom, established in 2016. The company specializes in the development and commercialization of innovative biodegradable drug delivery platforms aimed at treating chronic eye diseases, including age-related macular degeneration, diabetic retinopathy, glaucoma, and ocular infections. Re-Vana’s platforms, OcuLief and EyeLief, are designed for long-acting, tailored delivery of therapeutics, allowing for sustained release of active ingredients over periods ranging from one week to one year. OcuLief is specifically developed for age-related macular degeneration and diabetic retinopathy, while EyeLief targets glaucoma and retinal diseases. The company employs FDA-approved polymers in its technology, focusing on enhancing patient compliance by minimizing treatment frequency, reducing pain, and lowering side effects. By providing versatile delivery options, Re-Vana aims to facilitate cost savings for healthcare providers and pharmaceutical companies while improving patient outcomes.

Mojo Vision Inc. is a technology company based in Saratoga, California, founded in 2015. The company specializes in the development of augmented reality solutions, focusing on high-performance micro-LED display technology. Mojo Vision has created the world's smallest and densest dynamic display for smart contact lenses, which are designed to provide users with timely information seamlessly and hands-free, without the distractions associated with traditional mobile devices. The company is also engaged in a joint development agreement with Menicon Co., Ltd. to explore smart contact lens products, further enhancing its innovative offerings. By combining advanced display and semiconductor expertise with proprietary quantum-dot technology, Mojo Vision aims to revolutionize the display industry, addressing diverse applications across consumer, enterprise, and government sectors.

ONL Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies to protect and improve vision in patients with retinal diseases. Established in 2006, the company specializes in creating photoreceptor protective agents that target the FAS apoptotic pathway, offering potential protection for photoreceptors. Its drug programs are designed to address serious, vision-threatening conditions, including retinal detachment, ultimately aiming to enhance surgical outcomes and patient quality of life through the use of small-molecule peptides.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.

Pr3vent, Inc. is a technology company based in Palo Alto, California, that specializes in artificial intelligence and machine learning applications for screening ophthalmic conditions in newborns. Established in 2017, Pr3vent focuses on providing affordable and effective eye exams for infants, utilizing a wide-angle fundus camera to capture comprehensive images of the retina. Their advanced algorithms analyze these images to detect abnormalities and generate referral recommendations when necessary. By enabling timely examination and treatment, Pr3vent's innovative approach aims to prevent vision loss in babies, ensuring that potential issues are identified and addressed as early as possible.

IACTA Pharmaceuticals is a company focused on developing innovative eyecare products aimed at treating diseases and enhancing patient outcomes. The firm specializes in a hydrophobic drug designed for encapsulation and delivery to ocular tissues, which facilitates improved permeation and effectiveness in addressing conditions such as dry eye. IACTA Pharmaceuticals emphasizes the importance of collaboration among business partners, scientists, and patients, recognizing that successful pharmaceutical development extends beyond mere scientific advancement to include the insights and needs of the people involved.

Qura, Inc. is a biotechnology company based in Framingham, Massachusetts, focused on the development of micro-injectable implants and ultra-miniature devices designed to monitor physiological pressure changes. Established in 2013, Qura aims to transform physiological monitoring in biomedicine through innovative tools that continuously track health metrics, particularly in applications like glaucoma management. The company envisions a future where networks of smart, miniaturized devices communicate and respond in real-time, enabling both disease monitoring and the administration of timely treatments. This approach has the potential to enhance research capabilities and improve patient care outcomes while also reducing healthcare costs.

Alievio, Inc. is a North Carolina-based company that specializes in the design, development, and manufacturing of innovative ophthalmic medical devices for glaucoma patients. The company has introduced a novel device, Sollevio, which offers a noninvasive method for titrating postoperative intraocular pressure in the treatment of refractory glaucoma. This device serves as a significant advancement in glaucoma therapy, aiming to address the complications associated with traditional glaucoma surgeries while providing ophthalmologists with a valuable tool to halt the progression of the disease. Founded in 2010 and originally known as Camras Vision, Inc., Alievio changed its name in June 2019 and operates from Research Triangle Park, North Carolina.

Trefoil Therapeutics is a biotechnology company dedicated to developing innovative therapies for endothelial cell-mediated diseases, particularly those affecting the cornea. Utilizing its proprietary engineered fibroblast growth factor-1 technology platform, Trefoil aims to create first-in-class regenerative pharmacologic treatments for conditions such as Fuchs dystrophy and other serious corneal diseases that can lead to preventable blindness. The company is currently focused on a topical eye drop formulation known as TTHX1114, designed to treat ulcerative conditions on the cornea's surface, which can result in corneal scarring and significant vision loss. With a management team boasting over 100 years of combined experience in pharmaceutical development and commercialization, Trefoil strives to enhance human health through protein-engineered drug therapies. As an early-stage company, it has received recognition from the biopharmaceutical funding community for its innovative business approach.